Core Viewpoint - DENTSPLY SIRONA is undergoing a significant transformation under new CEO Daniel T. Scavilla, focusing on a return to growth through a comprehensive action plan aimed at improving customer experience, operational efficiency, and financial performance. Financial Performance - For Q3 2025, global sales were $940 million, a decrease of 5% as reported and 8% on a constant currency basis, with adjusted EBITDA at 18.4%, up 50 basis points from the prior year [8][10] - Non-GAAP earnings per share for the prior year was $0.37, down $0.13, attributed to sales mix impacts and higher tax rates [9] - Cash from operations was $79 million, with an ending cash balance of $363 million [10] - The company recorded a $263 million non-cash after-tax charge related to goodwill and intangible asset impairment [10] Regional Sales Performance - US sales were $291 million, down 22.2% year-over-year, while European sales increased by 9.9% [12][13] - Sales in the Rest of World segment were $231 million, showing slight declines, with notable growth in Australia and India [13] Strategic Initiatives - The return to growth action plan consists of four key pillars: putting customers at the center, reigniting the US business, empowering people, and evolving operations [17] - The company aims to enhance customer experience by creating a global customer service organization and improving support for field-based employees [20][21] - A comprehensive plan is in place to strengthen the US commercial foundation, including aligning teams and enhancing decision-making processes [21][22] Leadership Changes - Matthew E. Garth, the former CFO, has departed the company, and a transition plan is in place to ensure continuity [6][7] - The company is actively searching for a new CFO who can leverage data for strategic decision-making [70] Future Outlook - The revised outlook for 2025 includes net sales in the range of $3.6 billion to $3.7 billion, with constant currency sales expected to decline by 5% to 4% year-over-year [16] - The company plans to increase investments in R&D and clinical education to support growth initiatives [47][74] Market Positioning - DENTSPLY SIRONA is focusing on strengthening its relationships with dealers and enhancing its direct sales approach, particularly in the implant market [58][81] - The company recognizes the need for improved training and presence in the market to better serve dental professionals [81]

Financial Data and Key Metrics Changes - For Q3 2025, global sales were $904 million, a decrease of 5% as reported, or negative 8% on a constant currency basis [7] - Adjusted EBITDA was 18.4%, up 50 basis points versus the prior year, driven by lower sales on favorable product and geography mix [8] - Non-GAAP earnings per share was $0.37, down $0.13 versus the prior year, with approximately half of the decline reflecting impacts of sales mix and tariffs [9] Business Line Data and Key Metrics Changes - Sales in the U.S. were $291 million, down 22.2% year-over-year, driven by lower sales in Essential Dental Solutions, CAD/CAM, Imaging, and Implants [10] - European sales were $382 million, increasing 9.9% as reported, or 2.6% on a constant currency basis, driven by growth in Connected Technology Solutions and labs [10] - Wellspect Healthcare sales grew 9.3% in Europe on a constant currency basis, with significant growth in the Rest of World segment [12] Market Data and Key Metrics Changes - U.S. sales were down 22.2%, while European sales increased 9.9%, indicating a divergence in market performance [10] - The Rest of World sales were $231 million, down slightly versus the prior year, with strength in Essential Dental Solutions offset by declines in Connected Technology Solutions and implants [11] Company Strategy and Development Direction - The company is focusing on a return-to-growth action plan with four key pillars: putting customers at the center, reigniting the U.S. business, empowering people, and evolving operations [14] - A transition plan is in place following the departure of the CFO to ensure continuity and maintain financial discipline [6][20] - The company plans to increase investments in R&D to improve product development processes and enhance customer experience [24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the need for bold changes and emphasized a commitment to reposition the company as a market leader [27] - The revised outlook for 2025 includes net sales in the range of $3.6 billion to $3.7 billion, with constant currency sales expected to decline by 5% to 4% year-over-year [13] - Management expressed confidence in the company's potential and the importance of executing the return-to-growth plan [26] Other Important Information - The company recorded a $263 million non-cash after-tax charge related to the impairment of goodwill and intangible assets due to tariffs and lower projected volumes [9] - The Wellspect Healthcare business will play a key role in achieving financial goals, with a decision made to retain the business for greater strategic benefit [25] Q&A Session Summary Question: Insights on the U.S. market performance - Management indicated that the U.S. market's decline is due to multiple factors, including structural approach and execution issues [31][32] Question: Cadence of growth over the next two years - Management stated that while they desire to return to growth quickly, they need more time to refine the growth plan and establish a timeline for improvements [35][36] Question: Capital allocation philosophy and dividend importance - Management emphasized the need to explore the value of dividends and prioritize business growth and debt retirement [37][38] Question: R&D investment acceleration - Management confirmed plans to pull forward R&D investments to strengthen the company's position for 2026 and beyond [40][42] Question: Characteristics sought in a new CFO - Management is looking for a CFO who can analyze data effectively and communicate meaningful metrics to drive the company's return-to-health strategy [64][65]

Financial Performance - Dentsply Sirona reported a net loss of $428 million for the three months ended September 30, 2025, compared to a net loss of $495 million for the same period in 2024, reflecting a 13.5% improvement year-over-year[13]. - Total comprehensive loss for the nine months ended September 30, 2025, was $394 million, a decrease from $482 million in the same period of 2024, indicating an 18.3% reduction in losses[13]. - Net loss for the nine months ended September 30, 2025, was $453 million, compared to a loss of $482 million for the same period in 2024[19]. - The total comprehensive loss for the three months ended September 30, 2025, was $459 million, slightly higher than the $456 million reported in the same period of 2024[13]. - Comprehensive loss attributable to Dentsply Sirona was $458 million for the three months ended September 30, 2025, compared to $455 million in the prior year[13]. - For the nine months ended September 30, 2025, the net loss was $453 million, an improvement from a net loss of $482 million in the same period of 2024[13]. - The total comprehensive loss for the nine months ended September 30, 2025, was $395 million, compared to $484 million in the same period of 2024[13]. - The company continues to focus on improving its financial performance despite ongoing losses in both net and comprehensive categories[13]. Cash and Liquidity - Cash and cash equivalents increased to $363 million as of September 30, 2025, up from $272 million at the end of 2024, representing a 33.5% increase[15]. - Cash provided by operating activities for the nine months ended September 30, 2025, was $134 million, down from $374 million in 2024[19]. - The company reported a net increase in cash and cash equivalents of $91 million for the nine months ended September 30, 2025[19]. - Total cash and cash equivalents at the end of the period was $363 million, compared to $296 million at the end of September 2024[19]. - The company had $736 million available under lines of credit as of September 30, 2025[190]. Sales and Revenue - Total net sales for the three months ended September 30, 2025, were $904 million, a decrease of 4.9% compared to $951 million in the same period of 2024[29]. - For the nine months ended September 30, 2025, total net sales were $2,719 million, down 5.9% from $2,888 million in 2024[29]. - The Orthodontic and Implant Solutions segment saw a significant decline, with net sales dropping by $36 million (15.0%) to $205 million for the three months ended September 30, 2025, primarily due to lower volumes of clear aligners following the suspension of Byte sales[143][145]. - The United States region experienced a notable decline in net sales, down $83 million (22.2%) to $291 million for the three months ended September 30, 2025, primarily due to lower volumes of Byte products and CAD/CAM equipment[147][148]. - The Essential Dental Solutions segment saw a decrease in net sales by $12 million (3.4%) to $357 million for the three months ended September 30, 2025, mainly due to lower sales of preventive and restorative products[141][142]. - Net sales in Europe increased by $35 million (9.9%) to $382 million for the three months ended September 30, 2025, primarily due to higher volumes of treatment centers and imaging equipment[150][151]. Expenses and Costs - SG&A expenses decreased by $35 million (8.8%) to $355 million for the three months ended September 30, 2025, and by $149 million (12.3%) to $1,055 million for the nine months ended September 30, 2025, primarily due to lower marketing expenses and headcount costs[158]. - R&D expenses decreased by $3 million (9.2%) to $37 million for the three months ended September 30, 2025, and by $13 million (10.9%) to $110 million for the nine months ended September 30, 2025, as the company continues to prioritize investments in digital workflow solutions and product development[160]. - The company incurred restructuring and other costs of $18 million for the nine months ended September 30, 2025, compared to $45 million in the same period of 2024, a decrease of 60%[50]. - Restructuring costs decreased to $5 million for the three months ended September 30, 2025, from $23 million in the same period of 2024, and to $18 million for the nine months ended September 30, 2025, from $45 million in 2024[163]. Assets and Liabilities - Total assets decreased to $5,653 million as of September 30, 2025, down from $5,753 million at December 31, 2024, a decline of 1.7%[15]. - Long-term debt increased to $2,017 million from $1,586 million, representing a 27.2% increase[15]. - The accumulated deficit grew to $1,385 million as of September 30, 2025, compared to $835 million at the end of 2024, indicating a 65.8% increase[15]. - Dentsply Sirona's total equity decreased to $1,478 million from $1,943 million, a decline of 23.8%[15]. - The company's total net debt to total capitalization ratio increased to 57.9% as of September 30, 2025, compared to 48.9% at December 31, 2024[190]. Impairments and Charges - Goodwill asset impairment for the nine months ended September 30, 2025, was $409 million, compared to $504 million in 2024[19]. - The Company recorded pre-tax goodwill impairment charges of $262 million for the three months ended September 30, 2025, and $409 million for the nine months ended September 30, 2025, primarily related to the Implant & Prosthetic Solutions reporting unit[161][162]. - An additional pre-tax goodwill impairment charge of $253 million was recorded for the same reporting unit as of September 30, 2025, driven by lower-than-expected volumes[87]. Legal and Regulatory Matters - The Company is involved in multiple securities litigations, including a consolidated class action in the SDNY Court, with claims alleging violations of U.S. securities laws from June 9, 2021, to May 9, 2022[92]. - The Company continues to incur significant legal fees related to these pending cases and may face substantial damages if any lawsuits are decided adversely[107][108]. - The IRS is examining the Company's U.S. federal income tax returns for 2015 and 2016, proposing an adjustment that could result in additional federal income taxes on a distribution of $451 million related to a stock redemption[109]. - The SEC concluded its investigation of the Company and does not intend to recommend any enforcement action against it as of October 14, 2025[93]. Market Conditions and Challenges - The Company has experienced higher prices for certain raw materials, negatively impacting margins, and is facing challenges due to macroeconomic conditions affecting consumer confidence and discretionary spending[124][125]. - The Company delivered a one-year notice of non-renewal for its distribution agreements with Patterson Companies, which could materially affect its business if new agreements are not secured[132]. - The Company's operations in Israel, which contributed approximately 3% of consolidated net sales, remain unaffected by geopolitical conflicts, although sales to Turkey have been impacted by import restrictions[129][130].

Core Insights - Dentsply International reported quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.45 per share, and down from $0.50 per share a year ago, representing an earnings surprise of -17.78% [1] - The company posted revenues of $904 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.27%, but down from $951 million year-over-year [2] - Dentsply shares have declined approximately 33.5% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.47 on revenues of $931.32 million, and for the current fiscal year, it is $1.87 on revenues of $3.65 billion [7] Estimate Revisions - The trend of estimate revisions for Dentsply was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Performance - Net sales decreased by 50% year-over-year, reaching $904 million in Q3 2025 compared to $951 million in Q3 2024[9] - Constant currency net sales decreased by 80%, including a 55% impact from Q3 2024 Byte impact and ERP pre-buy[14, 16] - Adjusted EBITDA margin increased by 50 bps year-over-year to 184%[9, 11, 16] - Adjusted EPS decreased by 265% year-over-year to $037[9, 12, 16] - Operating cash flow was $79 million[9, 13] Segment Results - Connected Technology Solutions (CTS) sales decreased by 39% as reported and 70% in constant currency[17] - Essential Dental Solutions (EDS) sales decreased by 34% as reported and 62% in constant currency, primarily due to a $24 million Q3 2024 pre-buy[17] - Orthodontic and Implant Solutions (OIS) sales decreased by 150% as reported and 171% in constant currency, impacted by a ~$30 million Byte year-over-year impact[17] - Wellspect Healthcare sales increased by 156% as reported and 93% in constant currency[17] Geographic Performance - U S net sales decreased by 222% in constant currency, including a 125% impact from Q3 2024 Byte impact and ERP pre-buy, reaching $291 million[16] - Europe net sales increased by 26% in constant currency, reaching $382 million[16] - Rest of World net sales decreased by 09% in constant currency, reaching $231 million[16] Revised Outlook - The company revised its 2025 constant currency outlook to a decline of 5% to 4%[19] - The company maintains its reported sales outlook at $36 billion - $37 billion[19] - The company revised its adjusted EBITDA margin outlook to >18%[19] - The company revised its adjusted EPS outlook to ~$160[19]

Dentsply Sirona Reports Third Quarter 2025Results Charlotte, N.C., November 6, 2025 - DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2025 and introduced its Return-to-Growth action plan, a comprehensive strategy to improve performance and position the Company for sustained, profitable growth over the next 24 months. Third quarter net sales of $904 million decreased (5.0%) (decreased (8.0%) in constant currency) compared ...

Core Insights - Dentsply Sirona reported a net sales decrease of 5.0% to $904 million in Q3 2025, with a net loss of $427 million, an improvement from a loss of $494 million in Q3 2024 [2][3][7] - The company introduced a Return-to-Growth action plan aimed at improving performance and achieving sustained, profitable growth over the next 24 months [3][4] Financial Performance - Q3 2025 net sales of $904 million decreased by 5.0% year-over-year, with a constant currency decrease of 8.0% [2][9] - Adjusted earnings per diluted share were $0.37, down from $0.50 in Q3 2024, while adjusted EBITDA margin improved to 18.4% from 17.9% [2][11][45] - The company recorded a non-cash goodwill impairment charge of $263 million in Q3 2025, compared to $504 million in Q3 2024 [15][41] Return-to-Growth Action Plan - The action plan focuses on four key pillars: enhancing customer experience, reigniting U.S. business growth, empowering employees, and evolving operations for innovation [4][10] - Leadership changes have been made to support the action plan, including the appointment of a new Chief Commercial Officer and a Chief Transformation Officer [5][10] Revised Outlook - Dentsply Sirona revised its 2025 outlook, projecting net sales between $3.6 billion and $3.7 billion, with adjusted EPS expected to be approximately $1.60 [5][6] - The company anticipates a year-over-year sales decline of 5% to 4% in constant currency for 2025 [5] Segment and Geographic Performance - In Q3 2025, the Orthodontic and Implant Solutions segment saw a significant sales decline of 15.0%, while Wellspect Healthcare experienced a growth of 15.6% [12][13] - Geographic performance showed a 22.2% decline in the U.S., contrasted with a 9.9% increase in Europe [13][39] Cash Flow and Liquidity - Operating cash flow for Q3 2025 was $79 million, down from $141 million in Q3 2024, primarily due to unfavorable working capital changes [14] - The company had $363 million in cash and cash equivalents as of September 30, 2025 [14][21]

Core Insights - DENTSPLY SIRONA Inc. is set to report its third-quarter 2025 results on November 6, with expectations of mixed performance due to various market pressures [2][4]. Financial Performance - The Zacks Consensus Estimate for revenues is $901.6 million, while earnings are expected to be 45 cents per share. The company's own estimates are slightly higher for revenues at $904 million but lower for earnings at 42 cents per share [3]. - In the previous quarter, the company reported a 4.9% year-over-year decline in sales to $936 million, primarily due to weaknesses in Orthodontic & Implant Solutions and Connected Technology Solutions [5]. Market Conditions - The company is facing tariff-related cost pressures, subdued U.S. demand, and ongoing product transitions, which are expected to impact both revenues and margins in the upcoming quarter [4][6]. - Management has maintained its full-year outlook, indicating confidence in its cost structure despite the challenges [6]. Segment Analysis - **Essential Dental Solutions (EDS)**: Expected to show modest low-single-digit growth, with revenues estimated to decline 0.5% organically to $370.5 million, supported by stable patient traffic globally [7]. - **Orthodontic & Implant Solutions (OIS)**: Anticipated to be a significant drag, with a projected 19.7% organic revenue decline to $195.2 million, impacted by the phase-out of the Byte aligner business and weak implant demand [8][10]. - **Connected Technology Solutions (CTS)**: Expected to face continued weakness, with revenues estimated to decline 2.8% organically to $264.4 million, as U.S. dental offices reduce capital equipment purchases [11]. - **Wellspect Healthcare**: Projected to stabilize with a 0.9% organic revenue increase to $73.9 million, supported by new product introductions [12]. Earnings Prediction - The current model does not predict an earnings beat for DENTSPLY SIRONA, with an Earnings ESP of -2.46% and a Zacks Rank of 3 (Hold) [13][14].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Luminar Technologies, Inc., urging shareholders to contact the firm to discuss their rights and possible legal actions [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Luminar may seek corporate governance reforms, the return of funds to the company, court-approved financial incentive awards, or other relief and benefits [2][3]. - Shareholder involvement is emphasized as a means to improve company policies, practices, and oversight mechanisms, ultimately enhancing shareholder value [3]. Group 2: Firm's Background and Services - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].